DermKnowledgeBASE: Mucocutaneous Leishmaniasis

Mucocutaneous Leishmaniasis

Semantic LIterature Summary Engine (SLISE)

( SLISE(Summary) - Drag this link to bookmarks bar for instant search)

Skin Deep - A Dermatology Blog

Loading........Please wait.

The text is the summary of recent articles on Mucocutaneous Leishmaniasis at 75 thresold from National Library of Medicine (NLM). This information is subject to NCBI's Disclaimer and Copyright notice.


They are cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (ML), and visceral leishmaniasis (VL) [1]. Up to 2 million cases of leishmaniasis are reported annually worldwide [2]. By contrast, circulating Tregs from Mucosal leishmaniasis patients failed to normalize during treatment [3]. Clinical and laboratory profile of the diagnosed cases were analyzed in detail [4]. Only one case of CL (1 female) and mucocutaneous leishmaniasis (1 female) were observed during the study period [5].

Braziliensis infections manifest as Localized cutaneous leishmaniasis (CL) [6]. We included all studies reporting cure rate after cutaneous or mucosal leishmaniasis treatment with Systemic azole drugs, regardless of their design [7]. Genetic hybridization has been demonstrated to yield dramatic structural genomic variation, but whether such changes in gene dosage impact gene expression has not been formally investigated [8]. A Regional Information System (SisLeish) was created in order to provide knowledge of the Distribution and tendency of this disease to analyze and monitor the leishmaniasis status [9]. Moreover, the versatility of nanometric drug delivery systems for the deliberate transport of a range of molecules plays a pivotal role in the design of therapeutic strategies against leishmaniasis [10].

The nose was reconstructed using the local tissue displaced as flaps, and using cartilage grafts taken from the Nasal septum and the Ear shell [11]. Data from 2008 to 2014 registered in the notification records of the disease of the Information System of the Complaints of Notification (SINAN), and the data of the Information Department of the Unified Health System (DATASUS) available from 2007 to 2013 were used and analyzed in the light of the statistics of the Temporal series by the Prais-Winsten method and chi-squared test [12]. Real-time PCR assays showed a significantly higher AIM2 gene expression in Mucosal leishmaniasis (ML) compared with that in cutaneous leishmaniasis (CL) [13]. Additionally, AIM2 mRNA expression was significantly higher in lesions from poor responders than in lesions from good responders [14]. In situ protein quantification analyses revealed greater AIM2 expression in ML lesions than in CL lesions [15].

GP63 could be associated with reduced NLRP3 inflammasome expression in CL and ML patients [16]. We report an unusual presentation of cutaneous (CL) or mucocutaneous leishmaniasis (ML) in RA patients from an endemic area of leishmaniasis [17]. An unusual clinical form of this disease is leishmaniasis recidivans (LR), a prolonged, relapsing form of cutaneous leishmaniasis resembling tuberculosis of the skin that may persist for many years with a Chronic and relapsing course [18]. To our knowledge, there are no reports from Ethiopia, and mucocutaneous involvement of LR has not been described to date [19]. The cultural Distribution index represents the distribution rate of a given taxon among different cultural groups and was calculated as the ratio of the Number of groups using the taxon to the total number of groups cited [20].

Topical application of the remedies dominated the other means of administration and this deserves particular attention as the main treatments against Neotropical leishmaniasis are painful Systemic injections [21]. The diagnosis of MCL encompasses epidemiological, clinical and laboratory aspects [22]. Cutaneous (CL) and mucocutaneous leishmaniasis (ML) are caused by different species of the genus Leishmania, transmitted to humans by sandfly bites [23]. Further, in peripheral blood mononuclear Cells (PBMCs) from patients with cutaneous leishmaniasis, CpG treatment similarly exhibited a dose-response effect on the production of IFN-γ, IL-17, IL-10, and IL-13, with reductions observed at higher doses [24]. A noninvasive, extremely sensitive, and highly specific exam is critical, particularly for mucosal leishmaniasis (ML), in which a low parasite quantity is expected [25].

We aimed to compare the diagnostic accuracy of swab and Biopsy sample analysis using SYBR Green- and TaqMan-based real-time PCR (qPCR) assays with that of a composite reference standard consisting of the Montenegro skin test, serology, histopathology, smears, culture, and conventional PCR [26]. Moreover, qPCR achieved better performance than most existing techniques used for the diagnosis of ATL and also detected the Leishmania parasite in a greater proportion of patients than the associated histopathology, smear, culture, and conventional PCR techniques did [27]. Leishmania infection, and Leishmaniasis, following occupational exposure has been also reported [28]. The visceral form of Leishmaniasis has an estimated incidence of 500,000 new cases [29]. Herein, we describe a case of Mucosal leishmaniasis occurring in a farmer living in an endemic region, who was treated with golimumab because of psoriatic arthritis [30].

Herein, we report a patient with a positive history of mucocutaneous leishmaniasis who presented with an Orbital Mass with a histological profile of idiopathic Orbital Inflammation [31]. The aim of the present work was to evaluate the anti-leishmanicidal activity of this drug in 2 major species of Leishmania responsible for causing the American tegumentar leishmaniasis (L [32]. This study compared the diagnosis efficacy of microscopic examination versus polymerase chain reaction (PCR)-based methods and DNA sequencing using whole blood and skin Lesion samples from patients with suspected leishmaniasis [33]. Donovani in Sri Lanka with Localized cutaneous leishmaniasis (LCL) being the predominant form [34]. We present two cases of Oral leishmaniasis and discuss the different diagnostic strategies and treatment [35].

The scarcity of financial support, laboratory infrastructure and trained persons are the major obstacles in this reality [36]. Moreover, parasitological tests require invasive procedures and depend on restrictive conditions for the collection of biological sample, which limit their use in large-scale for epidemiological studies [37]. ELISA has been the most widely used serological method for the diagnosis of visceral leishmaniasis (VL) as it is easy to perform and has a low cost [38]. However, flaws in specificity are observed in the diagnosis of cutaneous leishmaniasis [39]. One patient developed a severe and fatal mucocutaneous leishmaniasis with no response to conventional antimonial therapy [40].

We measured the expression of CD27, CD28, CD45RO, CD127, PD-1 and CD57, together with interferon-γ and perforin [41]. Data on miltefosine, paromomycin and liposomal amphotericin B are extremely scarce [42]. In October 1991 to December 2014, the RF registered 89, leishmaniasis cases, including 83 imported cases from 24 countries and 6 local cases [43]. The obtained data on the local cases of visceral leisimaniasis in Dagestan and on its sporadic cases in Crimea suggest that it is necessary to conduct epidemiological, epizootological, and entomological surveys in the above areas and to develop a system for visceral leishmaniasis epidemiological surveillance encompassing the whole package of antiepidemic measures [44]. Furthermore, due to the resurgence of leishmaniasis worldwide and in particular the large increase of international tourism to the region, it seems pertinent to update the current epidemiological and clinical profile of leishmaniasis in northwestern-Argentina [45].

Additionally patients suffering from concomitant diseases, besides leishmaniasis, were assessed [46]. In this cross-sectional exploratory study, we addressed whether targets from the eicosanoid biosynthetic pathway, assessed by multiplexed expression assays in Lesion Biopsy and plasma specimens, could highlight a distinct biosignature in patients with mucocutaneous leishmaniasis (MCL) or localized cutaneous leishmaniasis (LCL) [47].

References: 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 ,

Press Refresh to fetch fresh content with references from pubmed. This content was cached on

comments powered by Disqus

|


This is an experimental application for healthcare professionals. The information presented here is not intended to diagnose, treat, cure or prevent any disease. Read disclaimer.

SkinHelpDesk.com - Evidence based skincare free

About Me

I have varied research interests ranging from eHealth, Health Information Exchange, Clinical Trials and Research, Contact Dermatitis, Bioinformatics, and Cosmetic Dermatology. I have work experience in Canada as an eHealth analyst, and in Dubai and India as a Specialist Dermatologist.

Address

Bell Raj Eapen
Hamilton, ON
Canada